Furthermore, although we assessed immune cell infiltration and PD-1/CTLA-4 expression in the study, more immunotherapy-relevant biomarkers, such as PD-L1 and tumor mutation burden, and mechanistic analyses required to clarify the distinct immunotherapy responses of ICC and HCC components. Here, CTLA4 is linked to intrahepatic cholangiocarcinoma.